In a world where biotech startups often burn millions before seeing a single dollar, Couragene stands out as a quiet anomaly. With a lean team of just 5 people and $0.8M in revenue, this stealth biotech is playing a completely different game—one that prioritizes product over PR.

"When your website gets zero traffic but you're generating revenue, you're either doing something wrong or everything right. Couragene is betting on the latter."

The tech stack reveals telling clues about their approach. Using Squarespace with Tailwind CSS and Bootstrap suggests they're not investing heavily in web infrastructure—because they don't need to. Their priority isn't user acquisition; it's product development. The presence of HSTS and Priority Hints shows they understand security and performance, but they're using off-the-shelf tools rather than building custom solutions.

• Revenue-first approach in a capital-intensive industry
• Deliberate obscurity as a competitive moat
• Minimal web presence suggests IP protection focus
• Likely B2B/strategic partnership model vs. direct-to-market